

IN THE CLAIMS:

1. (currently amended) ~~Isolated~~ Oligodeoxynucleotides ~~for stimulating an adjuvant or treating immune-related diseases~~, presented in General Formula:

[General Formula]: HKCGTTCRTGTCSGM (SEQ ID NO: 1)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; and M represents C or A.

2. (currently amended) ~~The Isolated~~ oligodeoxynucleotides ~~for stimulating an adjuvant or treating immune-related diseases according to the claim 1,~~
~~wherein the oligonucleotides further comprise five nucleotides~~, presented in following General Formula, at a 5'-terminal end and a 3'-terminal end:

[General Formula]: DKMHKCGTTCRTGTCSGMYK (SEQ ID NO: 2)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; D represents A, G or T; M represents C or A; M represents C or A; and Y represents C or T.

3-5. (canceled)

6. (currently amended) The oligodeoxynucleotides according to any of ~~the one of~~ claims 1 and 2, wherein the oligodeoxynucleotides have a phosphodiester bond or phosphorothioate bond between the nucleotides.

7. (currently amended) The oligodeoxynucleotides according to any of ~~the one of~~ claims 1 and 2, wherein the oligonucleotides are selected from the group consisting of oligonucleotide is 5'-AGCAGCGTTCGTGTCCGCCT-3' (SEQ ID NO: 3), 5'-AGCAGCGTTCGTGTGCCCT-3' (SEQ ID NO: 4), 5'-AGCAGCGTTCATGTCCGCCT-3' (SEQ ID NO: 5), 5'-AGCAGCGTTCGTGTCCGCCT-3' (SEQ ID NO: 6), 5'-GTATTCGTTCGTGTCTGCCT-3' (SEQ ID NO: 7) and 5'-TGACTCGTTCGTGTGCATG-3' (SEQ ID NO: 8).

8. (new) The oligonucleotide of claim 1, wherein said oligonucleotide is an adjuvant.

9. (new) The oligonucleotide of claim 2 wherein said oligonucleotide is an adjuvant.

10. (new) A composition comprising an isolated oligonucleotide having the nucleic acid sequence of SEQ ID NO: 3, wherein said oligonucleotide treats atopic dermatitis or protects normal immune cells when radiotherapy is applied.